Barclays raised the firm’s price target on Avantor to $25 from $23 and keeps an Overweight rating on the shares. The analyst previewed the Q3 earnings reports for the life science tools and diagnostics sector and dug into bioprocessing destocking and the risk of National Institutes of Health budget cuts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AVTR:
- Avantor initiated with a Market Perform at Bernstein
- Avantor announces creation of new Scientific Advisory Board
- TOMI announces partnership with Avantor to expand presence of SteraMist
- Avantor partners with Tobin Scientific to provide end-to-end solution
- Avantor participates in a conference call with JPMorgan